Israeli pharmaceutical giant Teva said that it will donate millions of doses of its anti-malarial drug hydroxychloroquine, which has been touted as a possible treatment for the coronavirus (COVID-19), to U.S. hospitals free of charge.

It said 6 million doses will be delivered by March 31 and more than 10 million in a month.

“We are committed to helping to supply as many tablets as possible as demand for this treatment accelerates, at no cost,” said Teva executive vice president Brendan O’Grady. “Immediately upon learning of the potential benefit of hyroxychloroquine, Teva began to assess supply and to urgently acquire additional ingredients to make more product while arranging for all of what we had to be distributed immediately.”

The company added that it will also conduct research to see if among its catalog of 3,500 drugs, others can be used to fight COVID-19.

Hydroxychloroquine is approved by the U.S. Food and Drug Administration for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. It is currently under investigation to determine its effectiveness against COVID-19.

According to a study on 24 patients with coronavirus conducted by Professor Didier Raoult, director of France’s Institut Hospitalo Universitaire for the study of infectious diseases, six days after the start of taking hydroxychloroquine, the virus had disappeared in three-quarters of people treated. However top scientists, including White House coronavirus task force member Anthony Fauci, have said that further study is necessary before they can encourage the pill’s use.

Support Jewish Journalism
with 2020 Vision

One of the most intriguing stories of the sudden Coronavirus crisis is the role of the internet. With individuals forced into home quarantine, most are turning further online for information, education and social interaction.

JNS's influence and readership are growing exponentially, and our positioning sets us apart. Most Jewish media are advocating increasingly biased progressive political and social agendas. JNS is providing more and more readers with a welcome alternative and an ideological home.

During this crisis, JNS continues working overtime. We are being relied upon to tell the story of this crisis as it affects Israel and the global Jewish community, and explain the extraordinary political developments taking place in parallel.

Our ability to thrive in 2020 and beyond depends on the generosity of committed readers and supporters. Monthly donations in particular go a long way in helping us sustain our operations. We greatly appreciate any contributions you can make during these challenging times. We thank you for your ongoing support and wish you blessings for good health and peace of mind.